Luvometinib: First Approval

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Luvometinib is an oral MEK1/2 inhibitor targeting MAPK pathway activation.
• Rare malignancies and diseases often involve abnormal MAPK signaling.
• Fosun Pharma developed luvometinib for unmet needs in rare conditions.

Purpose of the Study:

• To summarize luvometinib's development milestones.
• To highlight its first approval for specific rare diseases.

Main Methods:

• Review of luvometinib's development process.
• Analysis of clinical data leading to regulatory approval.

Main Results:

• Luvometinib received approval in China in May 2025.
• Indications include adult LCH/histiocytic neoplasms and pediatric NF1 with symptomatic PN.
• The approval covers patients aged ≥ 2 years with specific conditions.

Conclusions:

• Luvometinib represents a significant advancement in treating rare diseases.
• The drug offers a new therapeutic option for LCH and NF1 patients.
• This approval marks a key milestone for Fosun Pharma's rare disease portfolio.